Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its ...
Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...
Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...
Huahei Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus (HDV), ...
Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...
Chinese biotech Huahui Health has won conditional approval for Libevitug (libevitug) to treat adults with chronic hepatitis D ...
Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver ...
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen ...
19hon MSNOpinion
HHS has new vaccine rules. They're doomed to fail. | Opinion
Trying to import Denmark's vaccine schedule into the United States is like bolting a jet engine onto a toy plane.
Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intellige | Qilu Pharmaceutical has struck a ...
According to the Florida Department of Health’s website, the St. Johns County case was reported in January in a patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results